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Significance of the study
What is already known about this subject?
 ► A high proportion of adults in the USA consume di-
etary supplements, including selenium.
 ► Selenium supplementation has been associated with 
the development of type 2 diabetes in some studies.
What are the new findings?
 ► After 2.9 years of selenium supplementation with 
200 µg/day, selenium had no effect on insulin sen-
sitivity or β-cell function as compared with the pla-
cebo group.
 ► Stratification by sex and age revealed no effect mod-
ification in response to selenium.
How might these results change the focus of 
research or clinical practice?
 ► These results provide key information regarding a 
lack of adverse effect of selenium supplementation 
on insulin sensitivity in a clinical trial.
 ► This work does not support a major role for selenium 
in insulin sensitivity or β-cell function.
 ► These results provide key information for clinicians 
to convey to patients as the use of dietary supple-
ments continues in a large proportion of adults in 
the USA.
AbStrAct
Objective While controversial, observational and 
randomized clinical trial data implicate the micronutrient 
selenium (Se) in the development of type 2 diabetes (T2D). 
The aim of this study was to test the hypothesis that 
Se supplementation adversely affects pancreatic β-cell 
function and insulin sensitivity.
Research design and methods In a subset of 400 
individuals participating in a randomized, placebo-
controlled trial of Se at 200 µg/day for colorectal 
adenomatous polyps, fasting plasma glucose and insulin 
were measured before randomization and within 6 months 
of completing intervention. Change in the homeostasis 
model assessment-β cell function (HOMA2-%β) and 
insulin sensitivity (HOMA2-%S) were compared between 
arms. A subgroup of 175 (79 Se and 96 placebo) 
participants underwent a modified oral glucose tolerance 
test (mOGTT) at the end of intervention and change in 
glucose values was assessed.
Results No statistically significant differences were 
observed for changes in HOMA2-%β or HOMA2-%S 
between those who received Se compared with placebo. 
After a mean of 2.9 years on study, mean HOMA2-%β 
values were 3.1±24.0 and 3.1±29.8 for the Se and placebo 
groups, respectively (p=0.99). For HOMA2-%S, the values 
were −0.5±223.2 and 80.9±1530.9 for the Se and placebo 
groups, respectively (p=1.00). Stratification by sex or age 
did not reveal any statistically significant effects on insulin 
sensitivity by treatment group. For mOGTT, mean baseline 
fasting blood glucose concentrations were significantly 
higher among participants in the placebo group compared 
with the Se group (96.6±14.6 and 92.3±12.0, respectively; 
p=0.04), a trend which remained through the 20 min 
assessment.
Conclusions These findings do not support a significant 
adverse effect of daily Se supplementation with 200 µg/day 
of selenized yeast on β-cell function or insulin sensitivity 
as an explanation for previously reported associations 
between Se and T2D. Further clarification of longer term 
effects of Se is needed.
Clinical trial registry NIH Clinical  Trials. gov number 
NCT00078897.
InTROduCTIOn
The trace element selenium (Se) has anti-
oxidant physiological functions that were 
proposed to potentially reduce the risk for 
cancer.1–3 This hypothesis was tested in large, 
randomized clinical trials (RCTs) of Se and 
skin and prostate cancers and colorectal 
adenoma,1–3 with equivocal results. Secondary 
analyses were conducted within the Nutri-
tional Prevention of Cancer (NPC) trial of 
skin cancer prevention, where participants 
receiving Se had an increased risk for type 
2 diabetes (T2D) as compared with those 
receiving placebo.4 Later clinical trials, specif-
ically the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) and the Selenium 
Trial, showed no statistically significant overall 
increased risk for T2D risk after supplemen-
tation with 200 µg/day Se as compared with 
placebo.2 3 In contrast, results from observa-
tional studies have generally demonstrated 
an increased risk for T2D among those with 
higher blood or toenail Se concentrations.5–9 
However, these results are challenging to 
interpret because of marked geographical 
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variation in dietary intake of Se, which in turn elicits 
major differences in circulating concentrations of Se. In 
addition, the mechanism(s) whereby Se supplementation 
might lead to insulin resistance has yet to be determined, 
though there are several viable hypotheses.
At one time, Se was thought to be beneficial in rela-
tion to glucose homeostasis, having been shown in 
rodent models to have insulin mimetic effects10 and 
reduce insulin resistance.11 However, the agent used in 
these earlier experimental studies was selenate, an inor-
ganic form of SE that is present in only small amounts 
in the human diet. More recently, the focus of human 
research on the biological effects of ingested SE has 
generally been on selenoproteins, a family of proteins 
that incorporate the amino acids selenomethionine and 
selenocysteine and mediate the actions of Se.12 One such 
selenoprotein is glutathione peroxidase-1 (GPx-1), which 
has an important role in protection against oxidative 
damage.12 13 In addition to its physiological role, experi-
ments with mouse models have demonstrated that GPx-1 
overexpression results in hyperglycemia and hyperinsu-
linemia; consistent with this adverse effect, GPx-1 null 
animals exhibited better insulin sensitivity compared 
with wild-type mice.14 15
Because of the equivocal results for the impact of Se 
on T2D and insulin action, we sought to determine the 
effect of Se supplementation on β-cell function and 
insulin sensitivity by employing the homeostatic model 
assessment of β-cell function (HOMA2-%β) and insulin 
sensitivity (HOMA2-%S), and oral glucose tolerance 
tests (OGTT) as the primary endpoints. We addressed 
this objective within the context of the Selenium Trial, a 
randomized, placebo-controlled clinical trial of the effect 
of selenized yeast for prevention of colorectal adenomas.3
ReseaRCH desIgn and meTHOds
study population
Participants for this study were drawn from the Selenium 
Trial (NIH Clinical  Trials. gov number NCT00078897). 
The Selenium Trial has been described in detail previ-
ously.3 16 Briefly, this was a double-blind, placebo-con-
trolled trial where participants were randomized to 
receive either 200 µg/day of Se as selenized yeast or 
placebo to assess the effect of Se on the development 
of metachronous (ie, new or ‘recurrent’) colorectal 
adenomas. Participants in the trial were men and women 
between the ages of 40 and 80 years recruited from 
endoscopy clinics in Arizona, Colorado, Texas, and New 
York, with one or more colorectal adenomas of diam-
eter ≥3 mm. All trial participants were required to have 
undergone total colonoscopy and complete removal of 
all colorectal adenomas within the 6 months before regis-
tration. Management of study data and biospecimens was 
conducted at the University of Arizona Cancer Center 
(Tucson, Arizona, USA).16
A total of 400 participants were selected for a substudy 
using HOMA2 assessments. Participants were identified 
based on the availability of a baseline fasting blood draw, 
as well as a postintervention fasting blood draw within 
6 months of intervention completion. Exclusion criteria 
included having taken celecoxib before this arm of the 
original protocol of the Selenium Trial was discontinued 
as directed by the Food and Drug Administration,3 16 and 
not having a fasting blood draw both preintervention and 
postintervention. A stratified random sample of available 
individuals was then selected from the eligible partici-
pants, based on year of randomization, leaving 195 from 
the placebo group and 205 from the Se treatment group 
for inclusion in the present analyses. Of these partici-
pants, results for HOMA2 assessments were available for 
188 participants in the placebo group and 201 in the Se 
group. Based on a two-sample t-test, a sample size of 389 
allows us to obtain a power of 81% detecting an effect 
size of 0.29 Cohen’s d for changes in HOMA parame-
ters between the placebo and Se groups at a significance 
level of 5%.17 For the modified OGTT (mOGTT) study, 
a convenience sample of 175 participants was selected. 
All participants who remained on the trial near the end 
of follow-up were approached and asked if they would 
like to take part in the mOGTT substudy. Individuals who 
agreed to participate were then scheduled for the test, 
including 96 participants in the placebo group and 79 
from the intervention group. The conduct of the trial was 
in accordance with requirements of the local IRB at each 
study site.
exposure and outcome assessment
To assess the primary endpoints of β-cell function 
(HOMA2-%β) and insulin sensitivity (HOMA2-%S), 
we used the University of Oxford Diabetes Trials Unit 
HOMA2 calculator Application Programming Interface 
downloaded from http://www. dtu. ox. ac. uk/ homacalcu-
lator/ index. php. Fasting blood draws from participants 
at the end of the Selenium Trial were obtained.18 As 
described above, a total of 400 participants were selected 
from the Se intervention and placebo groups to ascertain 
if there were differences between them for insulin sensi-
tivity and β-cell function. For plasma glucose concentra-
tions, blood was drawn into a tiger top tube at each of the 
time points, processed and shipped directly to a commer-
cial laboratory (Sonora Quest, Tempe, Arizona, USA). 
Assessment of plasma insulin concentrations at each time 
point were determined in the laboratory of Dr Lawrence 
Mandarino at Arizona State University (Tempe, Arizona, 
USA) using immunoassays Alpco Immunoassays (Salem, 
New Hampshire, USA). Each sample from an individual 
was run in the same assay batch to avoid laboratory drift, 
along with five internal reference standards included in 
each batch. The coefficients of variation for glucose and 
insulin were less than 5%.
While HOMA2 measures are an efficient strategy for 
assessing insulin resistance in large epidemiological 
studies, they are unable to capture dynamic changes in 
insulin secretion and do not directly address function-
ality.19 We therefore selected a subset of the clinical trial 
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Table 1 Baseline characteristics of homeostatic model assessment study participants
Characteristic Placebo (N = 195) Selenium (N = 205) Total (N = 400) P value* 
Age 
  Mean (SD) 62.6 (8.5) 63.4 (9.3) 63.0 (8.9) 0.32 
  Median (Q1, Q3) 64.0 (57.0, 69.0) 63.0 (57.0, 71.0) 63.0 (57.0, 70.0)
Body mass index 
  Mean (SD) 29.2 (4.9) 29.2 (5.4) 29.2 (5.2) 0.99 
  Median (Q1, Q3) 29.2 (25.5, 32.4) 27.8 (25.6, 32.0) 28.5 (25.5, 32.3)
Selenium dietary intake (µg/day)† 
  Mean (SD) 107.8 (63.0) 101.7 (56.1) 104.6 (59.5) 0.32 
  Median (Q1, Q3) 93.7 (70.5, 128.9) 88.8 (65.1, 124.4) 91.1 (67.9, 126.0)
Selenium supplemental intake (µg/day) 
  Mean (SD) 7.7 (11.7) 5.5 (7.2) 6.5 (9.7) 0.03 
  Median (Q1, Q3) 10.0 (0.0, 10.0) 0.0 (0.0, 10.0) 0.0 (0.0, 10.0)
Plasma selenium (ng/mL)‡
  Mean (SD) 137.2 (24.2) 140.9 (27.8) 139.1 (26.1) 0.16 
  Median (Q1, Q3) 134.4 (121.7, 152.1) 136.0 (124.0, 155.5) 134.6 (122.6, 153.8)
Gender 
  Female 62 (31.8%) 74 (36.1%) 136 (34.0%) 0.36 
  Male 133 (68.2%) 131 (63.9%) 264 (66.0%)
Ethnicity 
  Non-Hispanic 186 (95.4%) 192 (93.7%) 378 (94.5%) 0.45 
  Hispanic 9 (4.6%) 13 (6.3%) 22 (5.5%)
Race 
  Native American 0 (0.0%) 2 (1.0%) 2 (0.5%) 0.21 
  Asian 1 (0.5%) 1 (0.5%) 2 (0.5%)
  African–American 8 (4.1%) 7 (3.4%) 15 (3.8%)
  Other 0 (0.0%) 4 (2.0%) 4 (1.0%)
  White 186 (95.4%) 191 (93.2%) 377 (94.3%)
Education 
  High school 43 (22.1%) 39 (19.1%) 82 (20.6%) 0.04 
  Some college 55 (28.2%) 78 (38.2%) 133 (33.3%)
  College degree 35 (17.9%) 36 (17.6%) 71 (17.8%)
  Postgraduate 57 (29.2%) 48 (23.5%) 105 (26.3%)
Cigarette smoking status 
  Current smoker 17 (8.9%) 22 (10.8%) 39 (9.9%) 0.5 
  Previous smoker 91 (47.6%) 104 (51.2%) 195 (49.5%)
  Never smoker 83 (43.5%) 77 (37.9%) 160 (40.6%)
Diabetes 
  No diabetes 176 (90.3%) 193 (94.1%) 369 (92.3%) 0.15 
  Has diabetes 19 (9.7%) 12 (5.9%) 31 (7.8%)
Personal history of cancer
  Never had cancer 185 (94.9%) 196 (95.6%) 381 (95.3%) 0.73 
  Had cancer 10 (5.1%) 9 (4.4%) 19 (4.8%)
Aspirin use in last 20 years 
  0–1 year 115 (59.0%) 115 (56.1%) 230 (57.5%) 0.19 
  1 to <5 years 40 (20.5%) 49 (23.9%) 89 (22.3%)
  5 to <10 years 16 (8.2%) 8 (3.9%) 24 (6.0%)
  10+ years 24 (12.3%) 33 (16.1%) 57 (14.3%)
Continued
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Characteristic Placebo (N = 195) Selenium (N = 205) Total (N = 400) P value* 
Non-steroidal anti-inflammatory drug use in last 20 years
  0 to <1 year 176 (90.3%) 176 (85.9%) 352 (88.0%) 0.03 
  1 to <5 years 9 (4.6%) 23 (11.2%) 32 (8.0%)
  5 to <10 years 3 (1.5%) 4 (2.0%) 7 (1.8%)
  10+ years 7 (3.6%) 2 (1.0%) 9 (2.3%)
Clinic
  Phoenix 142 (72.8%) 148 (72.2%) 290 (72.5%) 0.33 
  Colorado 43 (22.1%) 48 (23.4%) 91 (22.8%)
  Western New York 3 (1.5%) 0 (0.0%) 3 (0.8%)
  Tucson 7 (3.6%) 9 (4.4%) 16 (4.0%)
*t-test or analysis of variance for continuous variables, χ2 categorical variables.
†From Arizona Food Frequency Questionnaire.
‡From baseline plasma.
Table 1 Continued
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participants for assessment using the mOGTT method of 
Cobelli et al.19 20 Briefly, an 8-sample, 3-hour mOGTT was 
performed for each participant. The test was commenced 
after an overnight fast with 75 g oral dose of glucose, 
followed by intravenous blood draws at 0, 10, 20, 30, 
60, 90, 120 and 180 min. Glucose concentrations were 
measured as described above.
Measurement of plasma Se concentrations were 
performed with the AAnalyst 600 atomic absorption spec-
trometer (Perkin-Elmer, Norwalk, Connecticut, USA) 
with a THGA graphite furnace with Zeeman background 
correction and a Se electrodeless discharge lamp. Each 
participant’s samples were diluted with matrix modi-
fiers containing 0.01% nickel nitrate hexahydrate and 
0.0043% magnesium nitrate hexahydrate in 0.4% nitric 
acid and 0.2% triton X-100. Calibration standards were 
prepared using the method of additions. Known stan-
dards were included for every 10 samples, and each 
sample was run in triplicate.
Collection of sociodemographic, dietary and medical 
history data was performed using self-administered ques-
tionnaires on randomization to the Selenium Trial. The 
Arizona Food Frequency Questionnaire was employed 
for dietary data ascertainment and has been described in 
detail elsewhere.21
statistical analyses
Means, SD and other summary statistics for the overall 
population and by Se and placebo group were calculated 
using standard statistical methods. Univariate compari-
sons by treatment used t-tests or analysis of variance for 
normally distributed variables. For non-normally distrib-
uted variables, univariate comparisons used non-para-
metric methods. Outcome variables, HOMA2-%β and 
HOMA2-%S were calculated using the HOMA2 API 
Oxford University 2004 as described above. Change 
in outcome variables, HOMA2-%β and HOMA2-%S 
was calculated by subtracting pre-measurements from 
post-measurements. Outcome difference variables were 
log transformed to achieve normality if necessary. Differ-
ence variables were modeled using linear regression on 
Se/placebo group and adjusting for baseline HOMA2 
measurements, age, and gender. OGTT was log trans-
formed and then analyzed using a linear mixed model 
approach controlling for correlations between multiple 
observations per participant. All analysis were performed 
using Stata V.15.0.
ResulTs
Tables 1 and 2 present the baseline characteristics of the 
participants in the Se and placebo arms for the HOMA 
subgroup and the OGTT subgroup, respectively.
As reported in the primary analysis of the Selenium 
Trial, the two arms were generally well balanced in 
regard to participant composition, with no meaningful 
differences by age, BMI, dietary intake of Se, gender, 
race or ethnicity, smoking status, medical history of 
diabetes or cancer, aspirin use, or clinic site. However, 
within the HOMA subgroup, there was a statistically 
significant difference in supplemental Se intake at base-
line (p=0.03), non-steroidal anti-inflammatory drug use 
(p=0.03), and education (p=0.04), while education was 
the only variable that differed for the OGTT subgroup 
(p=0.04).
Table 3 shows the baseline (pre-supplementation) and 
follow-up results for HOMA2-%β and HOMA2-%S, after a 
mean of 2.9 years of supplementation with Se or placebo.
No statistically significant differences were observed 
for any of the assessments, with a mean change in 
HOMA2-%β of 3.1±29.8 for those who were in the placebo 
group and 3.1±24.0 for those in the Se treatment group 
(p=0.99). Similar non-significant results were observed 
for change in HOMA2-%S (p=0.40). A comparison of 
changes in HOMA2-%β and HOMA2-%S stratified by age 
and gender is presented in table 4; no statistically signifi-
cant relationship between Se supplementation and either 
outcome measure was observed within any stratum.
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Table 2 Baseline characteristics of oral glucose tolerance test study participants
Characteristic Placebo (N = 96) Selenium (N = 79) Total (N = 175) P value*
Age
  Mean (SD) 60.9 (8.5) 62.3 (8.9) 61.6 (8.7) 0.28 
  Median (Q1, Q3) 59.5 (53.5, 68.5) 64.0 (55.0, 70.0) 62.0 (55.0, 69.0)
Body mass index 
  Mean (SD) 29.8 (5.4) 28.5 (5.0) 29.2 (5.2) 0.11 
  Median (Q1, Q3) 28.9 (25.7, 32.8) 27.8 (25.5, 31.6) 28.3 (25.5, 32.6)
Selenium dietary intake (µg/day)† 
  Mean (SD) 105.5 (48.4) 105.9 (54.4) 105.6 (51.0) 0.96 
  Median (Q1, Q3) 92.4 (73.6, 128.8) 94.5 (72.9, 122.6) 93.7 (73.3, 123.7)
Selenium supplemental intake (µg/day)† 
  Mean (SD) 5.6 (7.1) 6.6 (7.1) 6.0 (7.1) 0.35 
  Median (Q1, Q3) 0.0 (0.0, 10.0) 7.1 (0.0, 10.0) 4.3 (0.0, 10.0)
Plasma selenium (ng/mL)‡ 
  Mean (SD) 139.7 (23.8) 136.8 (22.8) 138.4 (23.3) 0.42 
  Median (Q1, Q3) 136.3 (123.9, 157.7) 131.3 (118.1, 155.0) 133.5 (122.5, 156.1)
Gender 
  Female 27 (28.1%) 31 (39.2%) 58 (33.1%) 0.12 
  Male 69 (71.9%) 48 (60.8%) 117 (66.9%)
Ethnicity
  Non-Hispanic 91 (94.8%) 77 (97.5%) 168 (96.0%) 0.37 
  Hispanic 5 (5.2%) 2 (2.5%) 7 (4.0%)
Race 
  Other 3 (3.1%) 0 (0.0%) 3 (1.7%) 0.28 
  White 92 (95.8%) 78 (98.7%) 170 (97.1%)
  Mixed 1 (1.0%) 1 (1.3%) 2 (1.1%)
Education 
  Some high school 0 (0.0%) 5 (6.3%) 5 (2.9%) 0.04 
  High school 22 (22.9%) 12 (15.2%) 34 (19.4%)
  Some college 24 (25.0%) 26 (32.9%) 50 (28.6%)
  College degree 19 (19.8%) 18 (22.8%) 37 (21.1%)
  Postgraduate 31 (32.3%) 18 (22.8%) 49 (28.0%)
Cigarette smoking
  Current smoker 13 (13.8%) 6 (7.8%) 19 (11.1%) 0.45 
  Previous smoker 42 (44.7%) 36 (46.8%) 78 (45.6%)
  Never Smoker 39 (41.5%) 35 (45.5%) 74 (43.3%)
Diabetes 
  No diabetes 94 (97.9%) 78 (98.7%) 172 (98.3%) 0.68 
  Has diabetes 2 (2.1%) 1 (1.3%) 3 (1.7%)
Personal history of cancer
  Never had cancer 89 (92.7%) 78 (98.7%) 167 (95.4%) 0.06 
  Had cancer 7 (7.3%) 1 (1.3%) 8 (4.6%)
Aspirin use in last 20 years
  0–1 year 58 (60.4%) 45 (57.0%) 103 (58.9%) 0.86 
  1 to <5 years 20 (20.8%) 15 (19.0%) 35 (20.0%)
  5 to <10 years 5 (5.2%) 5 (6.3%) 10 (5.7%)
  10+ years 13 (13.5%) 14 (17.7%) 27 (15.4%)
Continued
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Characteristic Placebo (N = 96) Selenium (N = 79) Total (N = 175) P value*
Non-steroidal anti-inflammatory drug use in last 20 years 
  0 to <1 year 93 (96.9%) 72 (91.1%) 165 (94.3%) 0.31 
  1 to <5 years 2 (2.1%) 3 (3.8%) 5 (2.9%)
  5 to <10 years 0 (0.0%) 2 (2.5%) 2 (1.1%)
  10+ years 1 (1.0%) 2 (2.5%) 3 (1.7%)
Clinic 
  Phoenix 69 (71.9%) 57 (72.2%) 126 (72.0%) 0.68 
  Colorado 11 (11.5%) 7 (8.9%) 18 (10.3%)
  Tucson 16 (16.7%) 14 (17.7%) 30 (17.1%)
  Mayo 0 (0.0%) 1 (1.3%) 1 (0.6%)
*t-test or analysis of variance for continuous variables, χ2 categorical variables.
†From Arizona Food Frequency Questionnaire.
‡From baseline plasma.
Table 2 Continued
Table 3 Comparison of HOMA2-%β and HOMA2-%S before and after selenium supplementation
Placebo (n=188) Selenium (n=201) Total (n=389) P value
HOMA2-%β 
Baseline % beta cell function 
  Mean (SD) 95.5 (29.6) 97.6 (32.0) 96.6 (30.9) 0.51* 
  Median (Q1, Q3) 94.0 (77.0, 112.5) 91.9 (76.9, 112.4) 92.6 (77.0, 112.4)
Post % beta cell function 
  Mean (SD) 98.6 (37.2) 100.6 (34.0) 99.6 (35.6) 0.57 
  Median (Q1, Q3) 92.0 (76.3, 113.0) 93.8 (78.0, 114.2) 92.4 (76.9, 113.3)
∆ % beta cell function 
  Mean (SD) 3.1 (29.8) 3.1 (24.0) 3.1 (26.9) 0.99 
  Median (Q1, Q3) −0.2 (-11.0, 10.5) 1.5 (-11.1, 13.7) 0.4 (-11.0, 12.4)
HOMA2-%S
Baseline % insulin sensitivity 
  Mean (SD) 251.9 (423.1) 241.5 (316.2) 246.5 (371.3) 1.0† 
  Median (Q1, Q3) 140.8 (87.1, 289.1) 146.9 (77.4, 284.5) 144.3 (83.5, 284.9)
Post % insulin sensitivity 
  Mean (SD) 332.8 (1603.3) 241.0 (393.2) 285.4 (1149.2) 0.52 
  Median (Q1, Q3) 131.3 (74.0, 270.4) 136.1 (79.4, 284.4) 133.9 (79.0, 282.1)
∆ Insulin sensitivity 
  Mean (SD) 80.9 (1530.9) −0.5 (223.2) 38.9 (1075.6) 0.40 
  Median (Q1, Q3) −9.3 (-56.7, 31.4) −2.3 (-53.9, 43.5) −6.1 (-54.1, 34.2)
*Student’s t-test.
†Kruskal-Wallis test.
HOMA2-%β, homeostatic model assessment of β-cell function; HOMA2-%S, homeostatic model assessment of insulin sensitivity.
Epidemiology/health services research
Results for the OGTT assessment are presented in 
table 5, where glucose levels at baseline and 10, 20, 30, 
60, 90, 120 and 180 min are compared between the Se 
and placebo groups after 2.9 years of follow-up.
Mean fasting glucose concentrations were statistically 
significantly higher among participants in the placebo 
group (96.6±14.6 mg/dL) than for those in the Se group 
(92.3±12.0 mg/dL; p=0.04), and remained higher during 
the 10 min (p=0.07) and 20 min intervals (p=0.05). At 
the five remaining time points ranging from 30 to 180 
min, no differences in glucose concentrations were 
observed between the treatment groups. We additionally 
conducted an investigation of whether participants who 
had baseline glucose concentrations that were normal 
(<100 mg/dL), impaired (>100 and<126 mg/dL), or 
diabetic (>126 mg/dL) converted to any of these states 
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Table 4 Comparison of change in HOMA2-%β and HOMA2-%S before and after selenium supplementation, stratified by sex 
and age
N Average SD Max Min P value
HOMA2-%β 
Female Placebo 57 −2.7 17.2 30.9 −56.4 0.08*
Selenium 73 4.0 23.6 102.3 −61.0
Male Placebo 131 5.6 33.6 202.6 −67.2 0.41
Selenium 128 2.5 24.3 90.3 −65.0
Age <63 Placebo 87 1.8 33.3 202.6 −67.2 0.86
Selenium 95 2.6 24.2 90.3 −65.0
Age ≥63 Placebo 101 4.2 26.5 161.7 −52.2 0.84
Selenium 106 3.5 23.9 102.3 −61.0
HOMA2-%S 
Female Placebo 57 −58.6 631.7 2173.5 −4102.8 0.53†
Selenium 73 −4.3 194.9 656.0 −707.1
Male Placebo 131 141.6 1785.2 20 345.5 −731.5 0.50
Selenium 128 1.7 238.6 1483.6 −1165.7
Age <63 Placebo 87 170.7 2235.4 20 345.5 −4102.8 0.99
Selenium 95 2.0 288.1 1483.6 −1165.7
Age ≥63 Placebo 101 3.6 268.1 2173.5 −731.5 0.21
Selenium 106 −2.8 143.5 427.8 −707.1
*Student’s t-test.
†Kruskal-Wallis test.
HOMA2-%β, homeostatic model assessment of β-cell function; HOMA2-%S, homeostatic model assessment of insulin sensitivity.
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during the trial (data not shown). We found that there 
were no differences by Se treatment as compared with 
placebo in the proportion of participants who changed 
to either an improved or worsening glucose concentra-
tion or stayed the same (p=0.86).
COnClusIOns
The results of this clinical trial of supplementation with 
200 µg/day Se versus placebo demonstrated no effect 
of Se treatment on measures of insulin action or secre-
tion. These findings lend important evidence that Se 
supplementation for up to 3 years in older individuals 
does not elicit diabetogenic effects in humans and are in 
agreement with the majority of data from clinical trials 
of Se. In a comparison of HOMA2-%β and HOMA2-%S, 
no differences were observed between the Se treatment 
group and the placebo arm after a mean of 2.9 years of 
supplementation. For OGTT, there were differences in 
fasting glucose concentrations, which were significantly 
higher at time zero among those in the placebo group 
than those who took Se. This trend remained up to the 
20 min assessment, after which there were no differences 
between the two groups. Interestingly, the Uppsala Longi-
tudinal Study of Adult Men reported a similar phenom-
enon finding in that the male participants with higher 
plasma Se levels displayed lower early insulin response in 
baseline intravenous glucose tolerance tests.22 However, 
the authors also found no significant differences in 
OGTT or hyperinsulinemic euglycemic clamp among 
the men with higher plasma Se levels after 20 years of 
follow-up and thus considered the baseline early insulin 
response finding a consequence of multiple comparison 
testing.22 Regardless, placebo and Se treatment groups 
both had fasting glucose concentrations that, on average, 
were well within the normal range. These results indicate 
that further research regarding the potential for effects 
of Se on glucose and insulin metabolism is warranted.
The results of the present study for mOGTT in partic-
ular are reminiscent of the original hypothesis related 
to Se and diabetes, where it was proposed that Se might 
reduce risk for impaired insulin signaling.10 11 The 
concept that Se may be a risk factor, rather than protec-
tive, for diabetes gained momentum after the publication 
of secondary analyses of the Nutritional Prevention of 
Cancer (NPC) Trial.4 In that work, researchers compared 
the proportion of those with T2D who were random-
ized to the Se group to those in the placebo group after 
having been supplemented for an average of 7.7 years 
and found a statistically significantly increased risk for 
T2D among those who received 200 µg/day Se, with a 
HR and 95% CI of 1.55 (1.03 to 2.33).4 SELECT was the 
next large clinical trial to report findings among the 35 
000 male participants who were part of the trial to ascer-
tain whether 200 µg/day of Se supplementation could 
reduce the risk of prostate cancer.3 In this trial, no signif-
icant differences between the intervention and placebo 
 o
n
 24 July 2019 by guest. Protected by copyright.
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2018-000613 on 7 February 2019. Downloaded from 
8 BMJ Open Diab Res Care 2019;7:e000613. doi:10.1136/bmjdrc-2018-000613
Table 5 Comparison of oral glucose tolerance test results for selenium and placebo groups
Glucose concentrations 
(mg/dL) Placebo (N=96) Selenium (N=79) Total (N=175) P value*
Fasting 
  Mean (SD) 96.6 (14.6) 92.3 (12.0) 94.7 (13.6) 0.04 
  Median (Q1, Q3) 94.0 (87.0, 102.5) 91.0 (83.0, 101.0) 94.0 (85.0, 101.0)
10 min 
  Mean (SD) 116.7 (20.3) 111.4 (17.4) 114.3 (19.2) 0.07 
  Median (Q1, Q3) 111.5 (103.0, 127.0) 112.0 (103.0, 122.0) 112.0 (103.0, 125.0)
20 min 
  Mean (SD) 144.0 (25.5) 136.7 (21.4) 140.7 (24.0) 0.05 
  Median (Q1, Q3) 143.0 (125.0, 160.0) 135.0 (121.0, 149.0) 137.0 (122.0, 155.0)
30 min 
  Mean (SD) 161.1 (32.1) 155.2 (27.9) 158.4 (30.3) 0.21 
  Median (Q1, Q3) 154.0 (136.0, 185.0) 156.0 (134.0, 169.0) 154.5 (135.0, 177.0)
60 min 
  Mean (SD) 174.0 (53.5) 168.5 (42.4) 171.5 (48.8) 0.46 
  Median (Q1, Q3) 172.0 (132.5, 212.5) 166.0 (135.0, 201.0) 169.0 (133.0, 209.0)
90 min 
  Mean (SD) 155.6 (53.8) 151.5 (44.4) 153.7 (49.7) 0.59 
  Median (Q1, Q3) 146.0 (121.0, 192.0) 145.0 (120.0, 186.0) 145.0 (121.0, 190.0)
120 min 
  Mean (SD) 132.2 (49.8) 129.4 (41.4) 130.9 (46.1) 0.70 
  Median (Q1, Q3) 122.0 (95.0, 168.0) 119.0 (98.0, 161.0) 120.0 (97.0, 161.0)
180 min 
  Mean (SD) 86.6 (38.3) 78.7 (31.3) 83.0 (35.4) 0.15 
  Median (Q1, Q3) 76.0 (64.0, 98.0) 69.5 (58.0, 94.0) 74.0 (59.0, 97.0)
*Student’s t-test.
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groups were observed for T2D, with a HR (95% CI) of 
1.07 (0.94 to 1.22).2 For the parent trial of the present 
work, participants were supplemented with 200 µg/day 
Se for a mean of 2.9 years, and no overall effect of Se on 
the incidence of T2D was observed, with an OR (95% CI) 
of 1.25 (0.74–2.11).3 However, when conducting strati-
fied analyses, a significant increased odds for T2D was 
observed for participants older than the median age of 
63 years (OR 2.21; 95% CI 1.04 to 4.67).3 In the present 
study, we stratified for age based on the same cutpoint of 
63 years, but found no modification of effect for either 
HOMA estimate. For OGTT, we were unable to stratify by 
age due to the smaller sample size of that subgroup.
The results of the present study and from clinical trials 
overall differ from the general findings from observa-
tional studies, the majority of which have demonstrated 
positive, direct associations between Se and the devel-
opment of T2D.5 7–9 Further, within the Selenium Trial, 
we have previously reported the results of a cross-sec-
tional investigation of baseline Se and prevalent T2D 
that revealed statistically significantly increased odds of 
T2D among those who had the highest concentrations of 
blood Se levels, with an OR (95% CI) of 1.77 (1.16 to 2.71) 
for those in the highest tertile of Se versus the lowest.23 
The difference in the findings for the observational study 
as compared with the clinical trial results suggests several 
possibilities. These include reverse causation, whereby 
the pathology of T2D affects Se concentrations, or the 
presence of residual confounding in the observational 
studies.
First, if Se is a causal agent for T2D, it would be 
expected that supplementation with this agent would 
result in a markedly increased rate of development of 
T2D in those in the treatment group as compared with 
the placebo group, which did not occur in the SELECT 
or Selenium Trial.2 3 While a significantly increased risk 
of T2D was found with supplementation in the NPC Trial, 
it is possible that this finding was due to chance given the 
conflicting results from larger clinical trials.
Another consideration is related to timing and dura-
tion of Se exposure. In the clinical trials discussed above, 
supplement or placebo were generally administered to 
older participants for 5 years or less. In contrast, the 
observational studies may reflect longer term dietary 
exposure and as such it may be that higher consump-
tion of Se throughout the lifespan is associated with risk 
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for insulin dysregulation, while supplementation for a 
comparatively brief period is not. Another possibility is 
that there is a third factor that affects both Se status and 
risk of T2D that is not adequately controlled in obser-
vational studies. Most of the published work, including 
our own cross-sectional analyses,23 has included adjusted 
models for key variables such as BMI, age, and dietary 
intake of specific macronutrients. This suggests that 
there may be an as-yet unidentified confounding variable 
or that there is residual confounding that has not been 
completely accounted for in adjusted models and which 
can have a substantial effect on measures of association in 
observational association studies.24 If this is the case, the 
results from clinical trials must carry more weight when 
evaluating whether there is truly a causal relationship 
between Se and insulin resistance or T2D.
The strengths of the present work include the study 
design and the measured outcomes for insulin resistance, 
including HOMA2-%β, HOMA2-%S and mOGTT. This 
was a clinical trial of Se for the prevention of colorectal 
adenoma for which carefully annotated data were 
collected for the participants and which in turn allowed 
us to investigate the role of Se in insulin resistance in a 
prospective manner. The treatment and placebo arms of 
the trial were well-balanced for variables that may affect 
the results of observational studies. Thus, causality can 
be assessed with more rigor than in cross-sectional anal-
yses. In addition, a majority of large studies have relied 
on self-reports of T2D and/or use of diabetes medica-
tion to assess the endpoint. We specifically designed this 
substudy to capture biomarkers for insulin resistance in 
order to aid in elucidation of a potential mechanism of 
action. Nonetheless, there were limitations to the work 
that must be acknowledged. These include the rela-
tively small sample size as compared with the parent trial 
overall, which for OGTT prevented further exploration of 
potential effect modification by age, gender, and race or 
ethnicity. Although there was sufficient statistical power 
to detect a statistically significant difference between the 
two treatment groups, there remains a possibility that the 
null findings were due to the comparatively small sample 
size.
In conclusion, the results of clinical trial do not 
support a causal role for Se in the development of insulin 
resistance or T2D as shown by the lack of differences 
in HOMA2-%β or HOMA2-%S between groups who 
received Se or placebo for an average of 2.9 years. In addi-
tion, fasting blood glucose concentrations were higher 
for those in the placebo group compared with those in 
the Se treatment group. Further clarification of whether 
there are individual characteristics such as genotype that 
may influence response to Se is warranted.
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